Davis Polk & Wardwell and Jia Yuan Law Offices have advised Chinese clinical trial and research firm Hangzhou Tigermed Consulting on its $1.38 billion Hong Kong IPO, with Freshfields Bruckhaus Deringer and Zhong Lun Law Firm representing the sponsors.

Tigermed, which is already listed in Shenzhen, is the largest clinical research trial provider in mainland China. According to Reuters, Tigermed will sell 107.06 million shares in this IPO, which could make the deal the largest healthcare transaction in Asia this year, topping WuXi Biologics’ $984 million share placement in May.

The Jia Yuan Law Offices team advising on the deal was led by partners Wang Yuan and Fu Yangyuan.

Meanwhile, partners Zhang Jinquan, Zhu Ying, Zhong Yang and Li Xiang led the Zhong Lun Law Firm team.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.

Deals

Skadden, AMT, MHM, Davis Polk advise on Trial Holding’s $258 mln Japan IPO

by Nimitt Dixit |

Skadden, Arps, Slate, Meagher & Flom and Anderson Mori & Tomotsune have advised Japanese discount-store chain operator Trial Holdings on its $258 million initial public offering on the Tokyo Stock Exchange (TSE), the largest IPO of the year so far.

Deals

Cleary, Freshies lead on China shoemaker’s planned $1 bln HK IPO

by Rowena Muñiz |

Cleary Gottlieb Steen & Hamilton and JunHe are advising Chinese footwear and apparel maker Belle Fashion Group on its planned Hong Kong IPO that is set to raise between $500 million and $1 billion. Freshfields Bruckhaus Deringer and Haiwen & Partners are representing the joint sponsors.